image: Image Caption: Classical TRAIL signaling induced by ONC201.
Credit: GAD
A review in Genes & Diseases charts the development of dordaviprone, also known as ONC201, from an experimental compound into a treatment for a form of brain cancer. The article examines the biology behind its activity against H3 K27M-mutant diffuse midline glioma and outlines opportunities to improve responses and address resistance.
Prepared by a team at Karmanos Cancer Institute and Wayne State University School of Medicine, the review describes the drug's accelerated regulatory approval as a milestone for this disease. It also explains why understanding its mechanisms remains essential for refining treatment and evaluating potential applications beyond glioma.
ONC201 belongs to the imipridone family of compounds and can cross the blood–brain barrier. Its activity involves several interconnected pathways that disrupt cancer cell survival, including activation of the mitochondrial protein-degrading enzyme ClpP, stimulation of the integrated stress response and interference with dopamine receptor D2 signaling.
These effects can disturb mitochondrial energy production and activate apoptosis, the process through which damaged or unwanted cells are eliminated. The drug can also increase TRAIL signaling, which helps engage molecular death receptors on cancer cells. Together, these mechanisms distinguish ONC201 from treatments that act primarily through a single target.
H3 K27M-mutant tumors carry a histone alteration that disrupts gene regulation and reshapes cellular metabolism. These changes can create dependencies on mitochondrial function and stress-response pathways, offering vulnerabilities that ONC201 may exploit. The review connects this biological context with the clinical benefits observed in selected patients.
However, responses vary, and cancer cells can adapt. Resistance mechanisms discussed include changes in ClpP and activation of survival signals involving EGFR, MAPK and AKT. Understanding these escape routes could help guide combinations designed to prolong treatment benefit.
The article highlights biomarkers as another priority. Measuring features such as ClpP activity, stress-response signaling and receptor expression may eventually help identify patients most likely to respond and improve treatment monitoring. These candidate markers require further validation before they can reliably guide care.
Related compounds, including ONC206, ONC212 and ONC213, are also being developed to exploit overlapping or distinct metabolic vulnerabilities. Their potential should be assessed individually, alongside evaluation of dosing, treatment sequencing and safety.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
# # # # # #
Reference
Julio M. Pimentel, Jun-Ying Zhou, Gen Sheng Wu, ONC201/dordaviprone for H3 K27M-mutant tumors: Discovery, mechanisms, therapeutic potential, and future directions, Genes & Diseases, Volume 14, Issue 1, 2027, 102335, https://doi.org/10.1016/j.gendis.2026.102335
Funding
NIH P30CA022453
Journal
Genes & Diseases